FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-fast-track-designation-trispecific-antibody-IBI3003)